期刊
ADVANCED THERAPEUTICS
卷 4, 期 3, 页码 -出版社
WILEY
DOI: 10.1002/adtp.202000243
关键词
abscopal effect; anenestic response; bioorthogonal chemistry; immuno-oncology; local drug activation; platform technologies
资金
- National Institutes of Health [R21CA228997-01]
- National Science Foundation [1726724]
- Shasqi, Inc.
- Direct For Mathematical & Physical Scien
- Division Of Chemistry [1726724] Funding Source: National Science Foundation
The CAPAC platform uses click chemistry to activate cancer drugs at specific tumors with minimal systemic toxicity. The lead candidate SQ3370 showed a strong systemic anti-tumor response in mice and has the potential to benefit patients with micro-metastatic lesions.
While systemic immuno-oncology therapies have shown remarkable success, only a limited subset of patients benefit from them. The Click Activated Protodrugs Against Cancer (CAPAC) platform is a click chemistry-based approach that activates cancer drugs at a specific tumor with minimal systemic toxicity. The CAPAC Platform is agnostic to tumor characteristics that can vary across patients and hence applicable to several types of tumors. The benefits of SQ3370 (lead candidate of CAPAC) are described to achieve systemic anti-tumor responses in mice bearing two tumors. SQ3370 consists of a biopolymer, injected in a single lesion, followed by systemic doses of an attenuated protodrug of doxorubicin (Dox). SQ3370 is well-tolerated at 5.9-times the maximum dose of conventional Dox, increased survival by 63% and induces a systemic anti-tumor response against injected and non-injected lesions. The sustained anti-tumor response also correlates with immune activation measured at both lesions. SQ3370 can potentially benefit patients with micro-metastatic lesions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据